Myositis Ossificans clinical trials
The registry lists 24 studies for Myositis Ossificans across more than 10 countries. 5 are recruiting or about to start. 23 of them are mainly about Myositis Ossificans (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Myositis Ossificans studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Clementia Pharmaceuticals Inc. (7) · Regeneron Pharmaceuticals (5) · Ipsen (3) · Incyte Corporation (2) · Ashibio Inc (1) · Novartis Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · The International FOP Association (1)
What is being tested here
Drugs under test in Myositis Ossificans studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Garetosmab | 1 | 2 | 3 |
| Zilurgisertib | 1 | 0 | 2 |
| Palovarotene | 0 | 2 | 5 |
| Andecaliximab | 0 | 1 | 1 |
| Saracatinib | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Jul 2027To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva · Incyte Corporation
- Nov 2027IL1 Inhibition in FOP · University of California, San Francisco
Who these studies take
Of the 4 Myositis Ossificans studies recruiting now, 2 (50%) set no upper age limit and 1 (25%) stop at 75 or younger. 4 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (100%) | 4 (100%) |
| 18 | 4 (100%) | 4 (100%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 3 (75%) | 3 (75%) |
| 50 | 3 (75%) | 3 (75%) |
| 65 | 3 (75%) | 3 (75%) |
| 75 | 3 (75%) | 3 (75%) |
| 85 | 3 (75%) | 3 (75%) |
Across all 24 studies, recruiting or not: 42% stop at 75 or younger and 42% at 65; 67% take children; 0% are for women only and 4% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. search them.
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Not yet recruitingNCT07559513Phase 3
- The Fibrodysplasia Ossificans Progressiva (FOP) RegistryRecruitingNCT027451581 country
- A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)RecruitingNCT060896162 countries
- To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaRecruitingNCT05090891Phase 217 countries
- IL1 Inhibition in FOPRecruitingNCT067245621 country
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingNCT06508021Phase 2/31 country
- An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)Approved for marketingNCT07301450
- Saracatinib Trial TO Prevent FOPActive, not recruitingNCT04307953Phase 23 countries
- A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingNCT05394116Phase 318 countries
- A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).TerminatedNCT05039515Phase 214 countries
- A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT060646561 country
- A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.CompletedNCT05027802Phase 310 countries
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT02279095Phase 25 countries
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.CompletedNCT03312634Phase 311 countries
- Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and HemodialysisCompletedNCT05099445Phase 11 country
- Comparison Between CT and MRI in Preoperative Evaluation of Neurogenic Myositis Ossificans or Neurogenic Para-osteo-arthritisCompletedNCT03832556Not applicable1 country
- A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans ProgressivaCompletedNCT03188666Phase 28 countries
- Study of Single-Ascending Doses of DS-6016a in Healthy Japanese SubjectsCompletedNCT04818398Phase 11 country
- An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.CompletedNCT046653231 country
- Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult SubjectsCompletedNCT04829773Phase 11 country
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsCompletedNCT02190747Phase 23 countries
- In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) SubjectsTerminatedNCT02521792Phase 21 country
- A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT023222556 countries
- Urine Sample Collection From FOP PatientsCompletedNCT020663241 country